MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(47 sites)
United Kingdom
Aberdeen Royal Infirmary, Aberdeen Royal United Hospital, Bath Belfast City Hospital, Belfast Birmingham Heartlands Hospital, Birmingham Blackpool Victoria Hospital, Blackpool Royal Bournemouth Hospital, Bournemouth Southmead Hospital, Bristol Addenbrooke's Hospital, Cambridge Kent and Canterbury Hospital, Canterbury University Hospital of Wales, Cardiff St Richard's Hospital, Chichester Colchester Hospital, Colchester Castle Hill Hospital, Cottingham Russells Hall Hospital, Dudley Western General Hospital, Edinburgh Royal Devon and Exeter Hospital, Exeter Gloucestershire Royal Hospital, Gloucester Calderdale Royal Hospital, Halifax Huddersfield Royal Infirmary, Huddersfield Raigmore Hospital, Inverness Kettering General Hospital, Kettering Leicester Royal Infirmary, Leicester St John's Hospital, Livingston University College Hospital, London St George's Hospital, London Wythenshawe Hospital, Manchester Arrowe Park Hospital, Metropolitan Borough of Wirral The James Cook University Hospital, Middlesbrough Freeman Hospital, Newcastle upon Tyne Royal Gwent Hospital, Newport North Tyneside General Hospital, North Shields Northampton General Hospital, Northampton Norfolk and Norwich University Hospital, Norwich Nottingham City Hospital, Nottingham Churchill Hospital, Oxford Royal Berkshire Hospital, Reading Wexham Park Hospital, Slough Southampton General Hospital, Southampton Royal Stoke University Hospital, Stoke-on-Trent Sunderland Royal Hospital, Sunderland Good Hope Hospital, Sutton Coldfield Royal Cornwall Hospital, Truro Warwick Hospital, Warwick New Cross Hospital, Wolverhampton Worthing Hospital, Worthing Last updated November 2024